Nagoya City University

This study looks at 50 patients with HER2-positive metastatic breast cancer who have had a good response to anti-HER2 therapy for at least two years. Researchers will use a blood test called Signatera to check for tiny bits of cancer DNA. The goal is to learn if this test can hel…